Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron completed a registered public offering that raised approximately $5.0 million in gross proceeds to support continued development of its cell therapy candidate, laromestrocel. The company sold 5,617,648 shares of Class A common stock and pre-funded warrants to purchase 264,706 additional shares, each unit paired with 2.5 detachable common warrants to buy in total 14,705,885 shares. The combined public offering price was $0.85 per share unit and $0.849 per pre-funded warrant unit, and the pre-funded warrants were exercised in full at a nominal $0.001 per share concurrently with closing, contributing to the stated proceeds. Common warrants are immediately exercisable, expire in 24 months, and have an exercise price of $0.85. Placement agent compensation included a 7.0% cash fee, a 1.0% management fee and warrants for 411,765 shares with a $1.0625 exercise price. The company said net proceeds will fund clinical and regulatory work for laromestrocel across HLHS, Alzheimer’s disease and pediatric DCM, CMC and BLA readiness, capital expenditures, working capital and general corporate purposes. The purchase agreement imposes customary representations and limited lock-up restrictions, including a 60-day prohibition on certain issuances and a one-year restriction on variable rate transactions, subject to exceptions.
Longeveron Inc. is offering 5,617,648 shares of Class A common stock together with 14,044,120 Class A common warrants and pre-funded warrants and placement agent warrants that could result in up to 15,382,356 shares issuable upon exercise. The combined public offering price per share and accompanying warrants is $0.85 and the pre-funded warrant package is $0.849. The prospectus shows a total public offering price of $5,000,000.90 (assuming full exercise of pre-funded warrants) with estimated proceeds to the company before expenses of approximately $4.65 million and net proceeds after fees and expenses of about $4.3 million. Placement agent compensation includes a 7.0% cash fee, a 1.0% management fee, reimbursement of non-accountable expenses of $10,000, legal and out-of-pocket expenses of $100,000, and issuance of Placement Agent Warrants to purchase up to 411,765 shares at an exercise price of $1.0625.
The filing highlights clinical and regulatory progress for the company’s lead investigational product, laromestrocel (formerly Lomecel-B): full enrollment in the pivotal Phase 2b ELPIS II HLHS trial (enrollment completed June 24, 2025) with anticipated top-line results in Q3 2026; FDA designations for HLHS (Rare Pediatric Disease, Orphan Drug, Fast Track) and for mild Alzheimer’s disease (RMAT July 5, 2024; Fast Track July 16, 2024); FDA accepted IND for pediatric DCM (July 8, 2025) enabling a Phase 2 pivotal trial. The company reports a going concern qualification from auditors and states additional funding is required. Class A shares trade on Nasdaq under LGVN with a last reported sale of $1.27 on August 7, 2025. Warrant instruments will not be listed and are expected to have limited liquidity.
Longeveron Inc. (LGVN) filed Amendment No.1 to its Form S-1 to raise capital via a best-efforts placement of up to 3,846,154 Class A shares and 9,615,385 accompanying two-year warrants (2.5 warrants per share). The assumed combined price equals the 29 Jul 2025 closing price of $1.56, implying gross proceeds of c.$6.0 million and net proceeds of c.$5.2 million after 8% cash fees and expenses to H.C. Wainwright. Investors may elect pre-funded warrants ($0.001 exercise) to avoid breaching 4.99%/9.99% ownership caps. No escrow or minimum offering is required; the offer terminates 29 Aug 2025.
Proceeds will fund: 1) pivotal Phase 2b ELPIS II trial in hypoplastic left heart syndrome (fully enrolled; top-line 3Q26; RPD, Orphan & Fast Track designations); 2) adaptive seamless Phase 2/3 for mild Alzheimer’s disease (RMAT & Fast Track); 3) IND-cleared pivotal Phase 2 in paediatric dilated cardiomyopathy; 4) CMC scale-up via outsourced CDMO; and general working capital.
The filing reiterates a going-concern warning—cash burn exceeds resources and additional capital will be required. Post-offering share count could rise to 17.5 million Class A shares (90% of pre-offer float), with a further 13.7 million shares underlying new warrants, amplifying dilution risk. No market for the new warrants is expected. Management and 5% holders have agreed to 45-day lock-ups.